Major Milestone Achieved at 4Tissue®

We are proud to announce that 4Tissue has received approval from both the Belgian Federal Agency for Medicines and Health Products (FAMHP/FAGG) and the Ethics Committee (EC) to initiate our First-in-Human (FIH) clinical study.

This important achievement marks a significant step forward in the clinical development of our technology and reflects the dedication, expertise, and perseverance of our entire team and collaborators.

With these approvals in place, we are now positioned to initiate our FIH study in the coming months and generate the clinical evidence needed to advance our mission of developing innovative solutions that improve patient outcomes and support healthcare professionals.

We would like to sincerely thank everyone who contributed to reaching this milestone. This accomplishment is the result of years of hard work, collaboration, and commitment.

Stay tuned as we embark on this exciting next phase and take another important step toward bringing our innovation to patients.